Prognostic value of the MIB-1 labeling index for central neurocytomas

Neurology

Volumn 62, Issue 6, 2004, Pages 987-989

  Rades, Dirk ^a   Schild, Steven E ^b   Fehlauer, Fabian ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

KI 67 ANTIGEN;

ADOLESCENT; ADULT; ARTICLE; CANCER CONTROL; CANCER MORTALITY; CANCER SURVIVAL; CHILD; CLINICAL TRIAL; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; LABELING INDEX; MALE; META ANALYSIS; NEUROEPITHELIOMA; PRIORITY JOURNAL; PROGNOSIS; SCORING SYSTEM;

EID: 1842509957     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000115392.21898.E3     Document Type: Article

References (7)

1. Rades D, Fehlauer F. Treatment options for central neurocytoma. Neurology 2002;59:1268-1270.
2. Takao H, Nakagawa K, Ohtomo K. Central neurocytoma with craniospinal dissemination. J Neurooncol 2003;61:255-259.
3. Hassoun J, Gambarelli D, Grisoli F, et al. Central neurocytoma. An electron-microscopic study of two cases. Acta Neuropathol 1982;56:151-156.
4. Kaplan EL, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
5. Soylemezoglu F, Scheithauer BW, Esteve J, Kleihues P. Atypical central neurocytoma. J Neuropathol Exp Neurol 1997;56:551-556.
6. Brat DJ, Scheithauer BW, Eberhart CG, Burger PC. Extraventricular neurocytomas: pathologic features and clinical outcome. Am J Surg Pathol 2001;25:1252-1260.
7. Mackenzie IRA. Central neurocytoma. Histologic atypia, proliferation potential, and clinical outcome. Cancer 1999;85:1606-1610.